Privia Health Group Inc. fell to a 52‑week low of $19.52 per share, with the latest price trading around $19.56, down about 1.6% in pre‑market activity. The decline follows a year‑to‑date loss of 16.3% and a 14.5% drop over the past twelve months, leaving the company with a market value of roughly $2.5 billion.
For the second quarter of 2026, Privia reported adjusted earnings of $0.19 per share, surpassing Wall Street’s consensus estimate of $0.07. Revenue reached $632.6 million, exceeding the forecast of $597.8 million by about $34.8 million. Despite the earnings beat, investors expressed concerns about cash‑flow timing and slower growth prospects for the second half of the year, contributing to the stock’s pre‑market weakness.
Analyst price targets for Privia range from $24 to $40, suggesting the market may still view the shares as undervalued. Technical analysis from InvestingPro notes that the Relative Strength Index places the stock in oversold territory, reinforcing the perception of a potential rebound.
The broader market context includes recent strong performances from other InvestingPro picks such as Super Micro Computer and AppLovin, but Privia’s price action remains constrained by the mixed outlook for its growth trajectory.
